These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35961838)

  • 21. Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
    Lacaze P; Marquina C; Tiller J; Brotchie A; Kang YJ; Merritt MA; Green RC; Watts GF; Nowak KJ; Manchanda R; Canfell K; James P; Winship I; McNeil JJ; Ademi Z
    EClinicalMedicine; 2023 Dec; 66():102297. PubMed ID: 38192593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
    Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
    JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
    Jahn B; Santamaria J; Dieplinger H; Binder CJ; Ebenbichler C; Scholl-Bürgi S; Conrads-Frank A; Rochau U; Kühne F; Stojkov I; Todorovic J; James L; Siebert U
    Atherosclerosis; 2022 Aug; 355():15-29. PubMed ID: 35870306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening.
    Gidding SS; Kirchner HL; Brangan A; Howard W; Kelly MA; Myers KD; Morgan KM; Oetjens MT; Shuey TC; Staszak D; Strande NT; Walters NL; Yu KD; Wilemon KA; Williams MS; Sturm AC; Jones LK
    J Am Heart Assoc; 2023 Jul; 12(13):e030073. PubMed ID: 37382153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.
    Lázaro P; Pérez de Isla L; Watts GF; Alonso R; Norman R; Muñiz O; Fuentes F; Mata N; López-Miranda J; González-Juanatey JR; Díaz-Díaz JL; Blasco AJ; Mata P
    J Clin Lipidol; 2017; 11(1):260-271. PubMed ID: 28391894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Lozano P; Henrikson NB; Dunn J; Morrison CC; Nguyen M; Blasi PR; Anderson ML; Whitlock EP
    JAMA; 2016 Aug; 316(6):645-55. PubMed ID: 27532919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.
    Kerr M; Pears R; Miedzybrodzka Z; Haralambos K; Cather M; Watson M; Humphries SE
    Eur Heart J; 2017 Jun; 38(23):1832-1839. PubMed ID: 28387827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
    Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
    Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic identification of familial hypercholesterolemia within a single U.S. health care system.
    Abul-Husn NS; Manickam K; Jones LK; Wright EA; Hartzel DN; Gonzaga-Jauregui C; O'Dushlaine C; Leader JB; Lester Kirchner H; Lindbuchler DM; Barr ML; Giovanni MA; Ritchie MD; Overton JD; Reid JG; Metpally RP; Wardeh AH; Borecki IB; Yancopoulos GD; Baras A; Shuldiner AR; Gottesman O; Ledbetter DH; Carey DJ; Dewey FE; Murray MF
    Science; 2016 Dec; 354(6319):. PubMed ID: 28008010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults.
    Bellows BK; Khera AV; Zhang Y; Ruiz-Negrón N; Stoddard HM; Wong JB; Kazi DS; de Ferranti SD; Moran AE
    J Am Heart Assoc; 2022 Jun; 11(11):e025192. PubMed ID: 35583136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan.
    Kodera S; Morita H; Kiyosue A; Ando J; Takura T; Komuro I
    Circ J; 2018 Sep; 82(10):2602-2608. PubMed ID: 30033948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
    Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
    Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.